biodegradable sustained release drug delivery systems … · 2018. 1. 5. · systems implant...
TRANSCRIPT
Biodegradable Sustained Release Drug
Delivery Systems Fabricated using a
Dissolvable Hydrogel Template Technology
for the Treatment of Ocular Indications
Financial Disclosures
Presentation Overview
Drawback of Current Microparticle Technology Broad Particle Size Distribution
Current Microemulsion
Advantages of Ohr SR Microfabrication Narrow Particle Size Distribution
Current Microemulsion
Ohr SR Microfabrication
Ohr Technology vs. Other Ocular SR Systems
Characteristic
Bevacizumab Ranibizumab Aflibercept
External Systems
Implant Systems
Micro-emulsion
Ohr
Injectable through small gauge needle + + - - + + +
Sustained release (4-6 months) - - + + + + + +
Biodegradable: Does not require removal + + - - - - + + + +
Initial release is controlled and tunable - - - - - - + - + +
Simple formulation and process designed for fragile biologics
+ + + + - - + +
High drug loading capability - - - + - + +
Load different drugs into same particle - - - - - - - - + +
Microfabricated Microparticles Using a
Dissolvable Hydrogel Template Microparticles are Released by Dissolving Hydrogel Template in Water
Hydrogel template
Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery. The AAPS Journal. 2010;12(3):348-360.
Routes of Administration
Ohr Sustained Release Therapeutics
0 1 2 3 4 5 6
0
2 0
4 0
6 0
8 0
1 0 0
M o n th s
Cu
mu
lati
ve
Re
lea
se
(%
)
Ophthalmic Indication: Glaucoma Tunable release capabilities for a hydrophilic drug molecule
Burst Release
1 Month 3 Month 4 Month
Different formulations to meet desired target profiles
0 2 4 6 8 1 0
0
2 0
4 0
6 0
8 0
1 0 0
D a y s
Cu
mu
lati
ve
Re
lea
se
(%
)
Ophthalmic Indication: Glaucoma Layering process reduces burst release for a hydrophilic drug molecule
Layered Formulations
Non-Layered Formulation
0 1 2 3 4 5 6
0
2 0
4 0
6 0
8 0
1 0 0
M o n th s
Cu
mu
lati
ve
Re
lea
se
(%
)
Ophthalmic Indication: Glaucoma Layering process reduces burst release
Burst Release
1 Month 3 Month 4 Month
Before Layering
0 2 4 6 8 1 0
0
2 0
4 0
6 0
8 0
1 0 0
M o n th s
Cu
mu
lati
ve
Re
lea
se
(%
)
Ophthalmic Indication: Inflammation Tunable release profile obtained using biodegradable polymers
Polymer B
Polymer A
Polymer
A+B
0 1 2 3 4 5
0
2 0
4 0
6 0
8 0
1 0 0
M o n th s
Cu
mu
lati
ve
Re
lea
se
(%
)
Ophthalmic Indication: Steroid-Induced Glaucoma Sustained release obtained for a hydrophobic drug molecule
OHR1031
57% Drug Load
Ophthalmic Indication: Retinal Diseases Sustained release obtained for a biologic ~150 kDa
0 1 2 3
0
2 0
4 0
6 0
8 0
1 0 0
M o n th s
Cu
mu
lati
ve
Re
lea
se
(%
)
Polymer 1
Polymer 2
Summary
